Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 24, 2016 - Issue 5
Submit an article Journal homepage
1,218
Views
9
CrossRef citations to date
0
Altmetric
Letter to the Editor

Potential of Pegylated Interferon Alpha-2a in Behçet Uveitis: A Report of Five Cases

Philip BielefeldDepartment of Internal Medicine and Systemic Diseases, University Hospital, Dijon, France, Correspondence[email protected]
, MD,
Hervé DevilliersDepartment of Internal Medicine and Systemic Diseases, University Hospital, Dijon, France,
, MD,
Clémence DeschasseDepartment of Ophthalmology, University Hospital, Dijon, France,
, MD,
David SaadounDepartment of Internal Medicine 1, Groupe Hospitalier Pitié-Salpétrière, Paris, France, and
, MD, PhD,
Pascal SèveDepartment of Internal Medicine, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France
, MD, PhD,
Aurore MuselierDepartment of Internal Medicine and Systemic Diseases, University Hospital, Dijon, France,
, MD,
Catherine Creuzot-GarcherDepartment of Ophthalmology, University Hospital, Dijon, France,
, MD, PhD,
Jean-François BesancenotDepartment of Internal Medicine and Systemic Diseases, University Hospital, Dijon, France,
, MD &
Alain Marie BronDepartment of Ophthalmology, University Hospital, Dijon, France,
, MD show all
Pages 599-602 | Received 07 Sep 2014, Accepted 19 Jan 2015, Published online: 11 Mar 2015

References

  • Saadoun D, Cassoux N, Wechsler B, et al. Ocular manifestations of Behçet's disease. Rev Med Int. 2010;31:545–550
  • Comarmond C, Wechsler B, Bodaghi B, et al. Biotherapies in Behçet's disease. Autoimmun Rev. 2014;13:762–9
  • Narkewicz MR, Rosenthal P, Schwarz KB, et al. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr. 2010;51:183–186
  • Ridruejo E. Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Expert Opin Drug Saf. 2014;13:307–319
  • Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet. 1990;335:1078–1080
  • Deuter CM, Kötter I, Wallace GR, et al. Behçet's disease: ocular effects and treatment. Prog Retin Eye Res. 2008;27:111–136
  • Tsambaos D, Eichelberg D, Goos M. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res. 1986;278:335–336
  • Kötter I, Günaydin I, Zierhut M, et al. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum. 2004;33:320–335
  • Alpsoy E, Aktekin M, Er H, et al. A randomized, controlled and blinded study of papulopustular lesions in Turkish Behçet's patients. Int J Dermatol. 1998;37:839–842
  • Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. IMAJ. 2002;4:928–930
  • Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146:837–844
  • Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–1662
  • Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011;129:288–294
  • Zierhut M, Abu El-Asrar AM, Bodaghi B, et al. Therapy of ocular Behçet disease. Ocul Immunol Inflamm. 2014;22:64–76
  • Caliceti P. Pharmacokinetics of pegylated interferons: what is misleading? Dig Liver Dis 2004;36:334–339
  • Aljumah AA, Murad MH. Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: a systematic review and meta-analysis. Hepatol Res. 2015;43:1255–1263
  • Lightmann S, Taylor SRJ, Bunce C et al. Pegylated interferon alpha-2b reduces corticosteroid requirement in patients with Behcet's disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis. Epub ahead of print
  • Deuter CME, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum. 2010;62:2796–2805

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.